Kuros Biosciences Ltd (KURN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Kuros Biosciences Ltd (KURN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014382
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kuros Biosciences Ltd (Kuros Biosciences) is a biotechnology company that develops products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as well as on spinal fusion. Its pipeline of products includes MagnetOs Granules, MagnetOs Putty, KUR-111, KUR-113 and KUR-112. Kuros Biosciences uses a synthetic matrix technology with reliable and pressure resistant, rapid closure of the damaged tissues. The company’s lead sealant product is Neuroseal (KUR-023) developed as an adjunct to suturing for sealing of the dura after cranial surgery. Kuros Biosciences is headquartered in Schlieren, Switzerland.

Kuros Biosciences Ltd (KURN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Kuros Biosciences Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Kuros Biosurgery Raises Additional USD5 Million Financing 11
Kuros Biosurgery Raises USD15.34 Million in Venture Financing 12
Partnerships 13
Cytos Biotech Enters Into Research And Development Agreement With Walter Reed Army Institute 13
Merger 14
Cytos Biotech Merges with Kuros Biosurgery 14
Licensing Agreements 15
Checkmate Pharmaceuticals Enters into Licensing Agreement with Cytos Biotechnology 15
Cytos Biotechnology Enters into License Agreement with Novartis 16
Kuros Biosurgery Enters Into Licensing Agreement With Synthes 17
Equity Offering 18
Kuros Biosciences Raises Funds through Public Offering of Shares 18
Kuros Biosciences Raises Funds through Rights Offering of Shares 19
Cytos Biotechnology Completes Rights Offering Of Shares For US$26.7 Million 20
Cytos Biotechnology Completes Private Placement Of Shares For US$26 Million 21
Cytos Biotechnology Completes Rights Offering Of Shares For US$3.5 Million 23
Debt Offering 25
Cytos Biotechnology Announces Private Placement Of Secured Convertible Notes For US$14.5 Million 25
Kuros Biosciences Ltd – Key Competitors 27
Kuros Biosciences Ltd – Key Employees 28
Kuros Biosciences Ltd – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Sep 26, 2017: Kuros Biosciences Reports Financial Results for First Half-Year of 2017 30
Apr 26, 2017: Kuros Biosciences Reports Financial Results for 2016 31
Sep 29, 2016: Kuros Biosciences Reports Financial Results for First Half-Year of 2016 33
Apr 26, 2016: Kuros Biosciences Reports Financial Results for 2015 35
Corporate Communications 36
Nov 16, 2017: Kuros announces management changes 36
Apr 28, 2017: Kuros Biosciences Proposes Election of Four New Board Members 37
Apr 13, 2017: Kuros announces CEO succession 38
Other Significant Developments 39
Jan 08, 2016: Cytos Biotechnology will be renamed Kuros Biosciences 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kuros Biosciences Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Kuros Biosciences Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kuros Biosurgery Raises Additional USD5 Million Financing 11
Kuros Biosurgery Raises USD15.34 Million in Venture Financing 12
Cytos Biotech Enters Into Research And Development Agreement With Walter Reed Army Institute 13
Cytos Biotech Merges with Kuros Biosurgery 14
Checkmate Pharmaceuticals Enters into Licensing Agreement with Cytos Biotechnology 15
Cytos Biotechnology Enters into License Agreement with Novartis 16
Kuros Biosurgery Enters Into Licensing Agreement With Synthes 17
Kuros Biosciences Raises Funds through Public Offering of Shares 18
Kuros Biosciences Raises Funds through Rights Offering of Shares 19
Cytos Biotechnology Completes Rights Offering Of Shares For US$26.7 Million 20
Cytos Biotechnology Completes Private Placement Of Shares For US$26 Million 21
Cytos Biotechnology Completes Rights Offering Of Shares For US$3.5 Million 23
Cytos Biotechnology Announces Private Placement Of Secured Convertible Notes For US$14.5 Million 25
Kuros Biosciences Ltd, Key Competitors 27
Kuros Biosciences Ltd, Key Employees 28
Kuros Biosciences Ltd, Subsidiaries 29

★海外企業調査レポート[Kuros Biosciences Ltd (KURN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Compania Espanola de Petroleos SAU:企業の戦略的SWOT分析
    Compania Espanola de Petroleos SAU - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Gymboree Group, Inc.:企業の戦略的SWOT分析
    Gymboree Group, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Camlin Fine Sciences Ltd:企業の戦略・SWOT・財務情報
    Camlin Fine Sciences Ltd - Strategy, SWOT and Corporate Finance Report Summary Camlin Fine Sciences Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • WestRock Co:戦略・SWOT・企業財務分析
    WestRock Co - Strategy, SWOT and Corporate Finance Report Summary WestRock Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Vista Gold Corp.:企業の戦略・SWOT・財務情報
    Vista Gold Corp. - Strategy, SWOT and Corporate Finance Report Summary Vista Gold Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Bioxyne Ltd (BXN):製薬・医療:M&Aディール及び事業提携情報
    Summary Bioxyne Ltd (Bioxyne), is a biotechnology company that develops, manufactures, markets and commercializes healthcare products in the areas of immune health and immunotherapeutics. It manufactures consumer food supplements such as, ProTract and Progastrim, which are based on a proprietary pro …
  • Shopping Centres Australasia Property Group RE Limited:企業の戦略・SWOT・財務情報
    Shopping Centres Australasia Property Group RE Limited - Strategy, SWOT and Corporate Finance Report Summary Shopping Centres Australasia Property Group RE Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …
  • Immuron Ltd (IMC):企業の財務・戦略的SWOT分析
    Summary Immuron Ltd (Immuron), formerly Anadis Ltd is a biopharmaceutical company that develops oral immunotherapy therapeutics using polyclonal antibody products for humans. The company develops and produces an orally stable therapeutic for various immune mediated and inflammatory disorders. It pro …
  • Funtastic Ltd (FUN):企業の財務・戦略的SWOT分析
    Funtastic Ltd (FUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Awarepoint Corp:医療機器:M&Aディール及び事業提携情報
    Summary Awarepoint Corp (Awarepoint) is a healthcare technology company that provides real time location system. The company offers technology, software and managed services. It provides location software packages for mobile phones and other electronics. Awarepoint’s software packages provide patien …
  • Bhansali Engineering Polymers Ltd (BEPL):企業の財務・戦略的SWOT分析
    Summary Bhansali Engineering Polymers Ltd (BEPL), formerly Bhansali Steel Ltd is a petrochemical company that manufactures and markets acrylonitrile butadiene styrene. The company's products include general ABS, extrusion ABS, flame retardant ABS, ABS-GF or SAN-GF, PMMA-ABS, PVC modifier, PC or ABS …
  • Bridgeport Energy Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Bridgeport Energy Ltd (Bridgeport Energy), a subsidiary of New Hope Corporation Limited is an oil and gas company that explores, produces and develops oil and gas. The company acquires and operates oil and gas assets in Australia and internationally. It holds and operates assets located in t …
  • Navios Maritime Acquisition Corp:企業のM&A・事業提携・投資動向
    Navios Maritime Acquisition Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Navios Maritime Acquisition Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • Clinical Trial Consultants AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Clinical Trial Consultants AB (CTC AB) is a contract research organization that conducts hospital-based early phase clinical trials. The organization offers services which include pharmacovigilance, human PET imaging studies, medical and scientific advisory, quality assurance and outsourcing …
  • Inovise Medical, Inc.:企業の戦略的SWOT分析
    Inovise Medical, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • ITT Inc.:企業の戦略・SWOT・財務分析
    ITT Inc. - Strategy, SWOT and Corporate Finance Report Summary ITT Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • CooperVision Inc:医療機器:M&Aディール及び事業提携情報
    Summary CooperVision Inc (CooperVision), a subsidiary of The Cooper Companies Inc, designs and manufactures soft contact lenses. It manufactures a wide array of monthly, two-week and daily disposable contact lenses. CooperVision helps overcome various vision challenges such as astigmatism and presby …
  • Amil Assistencia Medica Internacional S/A:企業の戦略・SWOT・財務情報
    Amil Assistencia Medica Internacional S/A - Strategy, SWOT and Corporate Finance Report Summary Amil Assistencia Medica Internacional S/A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Petkim Petrokimya Holding AS (PETKM):企業の財務・戦略的SWOT分析
    Summary Petkim Petrokimya Holding AS (Petkim Petrokimya), a subsidiary of State Oil Company of the Azerbaijan Republic, is a chemical company. Its products portfolio includes propylene, acrylonitrile, ethylene, polyvinyl chloride, aromatics, polypropylene, sodium hydroxide, diethylene glycol, polyme …
  • AutoCanada Inc.:企業のM&A・事業提携・投資動向
    AutoCanada Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's AutoCanada Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆